Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

n the fair value for the first quarter 2011 consisted of $6.1 million due to an increase in the assessed probability of technical and regulatory success (PTRS) and $5.4 million due to the passage of time. The increase in the PTRS was due to the expanded size and change in endpoint of the Phase 3 European clinical trial, referred to as FOCUS or the "011" trial, announced in March 2011.

Interest ExpenseInterest expense of $5.0 million for the first quarter 2011 primarily relates to the 4.0% convertible senior notes due 2016 issued in August 2009 and includes non-cash imputed interest expense of $2.4 million as a result of the application of ASC 470-20.

Other ExpenseOther expense for the first quarter 2011 primarily consists of a $3.0 million impairment charge which reflects the reassessment of the fair value of Onyx's equity investment in S*BIO.

Cash, Cash Equivalents and Marketable SecuritiesOn March 31, 2011, cash, cash equivalents, and current and non-current marketable securities were $561.7 million compared to $577.9 million at December 31, 2010.  This excludes restricted cash of $31.9 million at December 31, 2010.  

Management Conference Call TodayOnyx will host a teleconference and webcast to provide a general business overview and discuss financial results.  The event will begin at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) on May 4, 2011.  Interested parties may access a live webcast of the presentation on the company's website at:

http://www.onyx-pharm.com/investors/event-calendar

or by dialing 888-771-4371 within the U.S. or 847-585-4405 outside the U.S., and using the passcode 29609004#.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 29609004# approximately one hour after the teleconference concludes for both US a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... 2015 Flexpoint Ford, a private equity firm ... announced that it has entered into a partnership with ... to form Kastle Therapeutics, LLC (Kastle).  The new company, ... on acquiring, developing and commercializing pharmaceuticals targeted toward diseases ... select therapies already approved for marketing, as well as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... 22, 2011 United Seating & Mobility (USM) ... transaction with Central Kentucky Mobility (CKM) to acquire and merge ... for Lexington, Louisville, as well as central, eastern and southern ... team strengthens our position within a core market for us ...
... WOONSOCKET, R.I., July 22, 2011 CVS Caremark Corporation ... conference call on Thursday, August 4, 2011, at 8:30 ... second quarter 2011 financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... will be broadcast simultaneously through the Investor Relations portion ...
Cached Medicine Technology:CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... The Clinical Data Interchange ... pleased to announce that data standards for clinical research in the areas of ... CDISC website . These three Therapeutic Area (TA) standards were developed per the ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing berry-flavored ... a simple way to get the natural ingredients that may help with body ...
(Date:7/30/2015)... ... ... Google recently announced that it will be disclosing any incidents involving its ... 8, 2015 article published by Nasdaq , the powerful tech company maintains that ... cars, which such industry players as Tesla CEO Elon Musk believe may very well ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Center,” to announce its position as one of Medicare’s top-rated care centers. ... members support the CMS rating system, which monitors health inspections, staffing, and ...
(Date:7/30/2015)... ... 2015 , ... Zejax is a New Way of Training ... , World renown body weight trainer, Paul Ziachik, announces today that he ... a person’s training capability. , The American College of Sports Medicine states that ...
Breaking Medicine News(10 mins):Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
... is a common problem in patients with chronic rhinosinusitis ... function, and quality of life (QOL), according to new ... Otolaryngology Head and Neck Surgery . ... and may have the following symptoms for 12 weeks ...
... 1, 2011) Endoscopic removal of pre-cancerous cells ... recommended rather than surveillance, according to a new ... Esophagus," published by the American Gastroenterological Association (AGA) ... Gastroenterology , the official journal of the ...
... Lymph node dissection, the current standard surgical treatment for ... screen-detected early stage cases , according to a study published ... Oncology (JTO), the official journal of the International Association ... nodal involvement is very low in early-stage cancers with a ...
... and Opportunistic Infections is taking place at the Hynes ... 2. Day two of this major HIV/AIDS research conference ... the National Institute of Allergy and Infectious Diseases (NIAID), ... HIV/TB Co-Infection , Diane Havlir, M.D., of the ...
... hundred years ago are being used in the development of ... time old bones have been used in this way. ... latest computer modelling techniques developed at the University of Leeds, ... With Engineering and Physical Sciences Research Council (EPSRC) funding, ...
Cached Medicine News:Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2Health News:Effects of depression on quality of life improvement after endoscopic sinus surgery 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 2Health News:Watchful waiting no longer recommended for some high-risk Barrett's esophagus patients 3Health News:Lymph node dissection is not essential in small screen-detected lung cancers, new research shows 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 2Health News:CROI -- Day 2: Selected highlights of NIH-supported research 3Health News:CROI -- Day 2: Selected highlights of NIH-supported research 4Health News:Learning from old bones to treat modern back pain 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: